Dual therapy with oral anticoagulation and single antiplatelet agent versus monotherapy with oral anticoagulation alone in patients with atrial fibrillation and stable ischemic heart disease: a systematic review and meta-analysis.
Humans
Platelet Aggregation Inhibitors
/ therapeutic use
Atrial Fibrillation
/ diagnosis
Treatment Outcome
Myocardial Ischemia
/ complications
Anticoagulants
/ therapeutic use
Hemorrhage
/ chemically induced
Stroke
Myocardial Infarction
/ complications
Fibrinolytic Agents
/ adverse effects
Vitamin K
Administration, Oral
Anticoagulation
Antiplatelet
Atrial fibrillation
Coronary artery disease
Stable ischemic heart disease
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
13
07
2022
accepted:
12
08
2022
pubmed:
10
9
2022
medline:
4
3
2023
entrez:
9
9
2022
Statut:
ppublish
Résumé
In patients with atrial fibrillation (AF) and stable ischemic heart disease, recent guidelines recommend oral anticoagulant (OAC) monotherapy in preference to OAC + single antiplatelet agent (SAPT) dual therapy. However, these data are based on the results of only two randomized controlled trials (RCTs) and a relatively small group of patients. Thus, the safety and efficacy of this approach may be underpowered to detect a significant difference. We hypothesized that OAC monotherapy will have a reduced risk of bleeding, but similar all-cause mortality and ischemic outcomes as compared to dual therapy (OAC + SAPT). A systematic search of PubMed/MEDLINE, EMBASE, and Scopus was conducted. Safety outcomes included total bleeding, major bleeding, and others. Efficacy outcomes included all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and major adverse cardiovascular events (MACE). RCTs and observational studies were pooled separately (study design stratified meta-analysis). Subgroup analyses were performed for vitamin K antagonists and direct oral anticoagulants (DOACs). Pooled risk ratios (RR) with corresponding 95% confidence intervals (CI) were calculated using the Mantel-Haenszel method. Meta-analysis of 2 RCTs comprising a total of 2905 patients showed that dual therapy (OAC + SAPT) vs. OAC monotherapy was associated with a statistically significant increase in major bleeding (RR 1.51; 95% CI [1.10, 2.06]). There was no significant reduction in MACE (RR 1.10; [0.71, 1.72]), stroke (RR 1.29; [0.85, 1.95]), myocardial infarction (RR 0.57; [0.28, 1.16]), cardiovascular mortality (RR 1.22; [0.63, 2.35]), or all-cause mortality (RR 1.18 [0.52, 2.68]). Meta-analysis of 20 observational studies comprising 47,451 patients showed that dual therapy (OAC + SAPT) vs. OAC monotherapy was associated with a statistically significant higher total bleeding (RR 1.50; [1.20, 1.88]), major bleeding (RR = 1.49; [1.38, 1.61]), gastrointestinal bleeding (RR = 1.62; [1.15, 2.28]), and myocardial infarction (RR = 1.15; [1.05, 1.26]), without significantly lower MACE (RR 1.10; [0.97, 1.24]), stroke (RR 0.93; [0.73, 1.19]), cardiovascular mortality (RR 1.11; [0.95, 1.29]), or all-cause mortality (RR 0.93; [0.78, 1.11]). Subgroup analysis showed similar results for both vitamin K antagonists and DOACs, except a statistically significant higher intracranial bleeding with vitamin K antagonist + SAPT vs. vitamin K antagonist monotherapy (RR 1.89; [1.36-2.63]). In patients with AF and stable ischemic heart disease, OAC + SAPT as compared to OAC monotherapy is associated with a significant increase in bleeding events without a significant reduction in thrombotic events, cardiovascular mortality, and all-cause mortality.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with atrial fibrillation (AF) and stable ischemic heart disease, recent guidelines recommend oral anticoagulant (OAC) monotherapy in preference to OAC + single antiplatelet agent (SAPT) dual therapy. However, these data are based on the results of only two randomized controlled trials (RCTs) and a relatively small group of patients. Thus, the safety and efficacy of this approach may be underpowered to detect a significant difference. We hypothesized that OAC monotherapy will have a reduced risk of bleeding, but similar all-cause mortality and ischemic outcomes as compared to dual therapy (OAC + SAPT).
METHODS
METHODS
A systematic search of PubMed/MEDLINE, EMBASE, and Scopus was conducted. Safety outcomes included total bleeding, major bleeding, and others. Efficacy outcomes included all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, and major adverse cardiovascular events (MACE). RCTs and observational studies were pooled separately (study design stratified meta-analysis). Subgroup analyses were performed for vitamin K antagonists and direct oral anticoagulants (DOACs). Pooled risk ratios (RR) with corresponding 95% confidence intervals (CI) were calculated using the Mantel-Haenszel method.
RESULTS
RESULTS
Meta-analysis of 2 RCTs comprising a total of 2905 patients showed that dual therapy (OAC + SAPT) vs. OAC monotherapy was associated with a statistically significant increase in major bleeding (RR 1.51; 95% CI [1.10, 2.06]). There was no significant reduction in MACE (RR 1.10; [0.71, 1.72]), stroke (RR 1.29; [0.85, 1.95]), myocardial infarction (RR 0.57; [0.28, 1.16]), cardiovascular mortality (RR 1.22; [0.63, 2.35]), or all-cause mortality (RR 1.18 [0.52, 2.68]). Meta-analysis of 20 observational studies comprising 47,451 patients showed that dual therapy (OAC + SAPT) vs. OAC monotherapy was associated with a statistically significant higher total bleeding (RR 1.50; [1.20, 1.88]), major bleeding (RR = 1.49; [1.38, 1.61]), gastrointestinal bleeding (RR = 1.62; [1.15, 2.28]), and myocardial infarction (RR = 1.15; [1.05, 1.26]), without significantly lower MACE (RR 1.10; [0.97, 1.24]), stroke (RR 0.93; [0.73, 1.19]), cardiovascular mortality (RR 1.11; [0.95, 1.29]), or all-cause mortality (RR 0.93; [0.78, 1.11]). Subgroup analysis showed similar results for both vitamin K antagonists and DOACs, except a statistically significant higher intracranial bleeding with vitamin K antagonist + SAPT vs. vitamin K antagonist monotherapy (RR 1.89; [1.36-2.63]).
CONCLUSIONS
CONCLUSIONS
In patients with AF and stable ischemic heart disease, OAC + SAPT as compared to OAC monotherapy is associated with a significant increase in bleeding events without a significant reduction in thrombotic events, cardiovascular mortality, and all-cause mortality.
Identifiants
pubmed: 36085242
doi: 10.1007/s10840-022-01347-1
pii: 10.1007/s10840-022-01347-1
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Anticoagulants
0
Fibrinolytic Agents
0
Vitamin K
12001-79-5
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
493-506Subventions
Organisme : Academy of Teaching Scholars, University of Oklahoma Health Sciences Center
ID : ATS
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lip GYH, Laroche C, Dan G-A, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16:308–19.
doi: 10.1093/europace/eut373
pubmed: 24351881
Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6:e24964.
doi: 10.1371/journal.pone.0024964
pubmed: 21957469
pmcid: 3177852
Cheung CC, Nattel S, Macle L, Andrade JG. Atrial fibrillation management in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines. Can J Cardiol. 2021;37(10):1607–18. https://doi.org/10.1016/j.cjca.2021.06.011 .
Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. Circ Am Heart Assoc. 2014;130:1749–67.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes. Circ Am Heart Assoc. 2014;130:e344–426.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.
doi: 10.1093/eurheartj/ehx393
pubmed: 28886621
Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103–13.
doi: 10.1056/NEJMoa1904143
pubmed: 31475793
Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circ Am Heart Assoc. 2019;139:604–16.
Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley; 2008 [cited 2021 Jan 26]. Available from: https://doi.org/10.1002/9780470712184 .
Moher D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264.
doi: 10.7326/0003-4819-151-4-200908180-00135
pubmed: 19622511
Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation. Available from: www.covidence.org .
Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928.
doi: 10.1136/bmj.d5928
pubmed: 22008217
pmcid: 3196245
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009. Available from: http://www.ohrica/programs/clinical_epidemiology/oxfordasp .
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.
doi: 10.1016/j.cct.2006.04.004
pubmed: 16807131
Review Manager (RevMan) [Computer program]. Cochrane Collaboration. 2020.
Antithrombotic therapy for atrial fibrillation with stable coronary disease. NEJM. [cited 2022 Jan 25]. Available from: https://doi.org/10.1056/nejmoa1904143 .
Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circ Am Heart Assoc. 2019;139:604–16.
Knight S, McCubrey RO, Yuan Z, et al. Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. Ther Adv Cardiovasc Dis. 2016;10:231–41.
doi: 10.1177/1753944716634563
pubmed: 26920371
pmcid: 5942628
Fukamachi D, Okumura Y, Yokoyama K, et al. Adverse clinical events in Japanese atrial fibrillation patients with and without coronary artery disease-findings from the SAKURA AF Registry. Curr Med Res Opin. 2019;35:2053–62.
doi: 10.1080/03007995.2019.1650014
pubmed: 31355684
Lamberts M, Gislason GH, Lip GYH, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant. Circ Am Heart Assoc. 2014;129:1577–85.
Wei L, Su E, Liu W, et al. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation. BMC Cardiovasc Disord. 2020;20:323.
doi: 10.1186/s12872-020-01609-8
pubmed: 32631244
pmcid: 7339421
Lamberts M, Lip GYH, Ruwald MH, et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. J Am Coll Cardiol. 2014;63:2689–98.
doi: 10.1016/j.jacc.2014.03.039
pubmed: 24794118
Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol Elsevier. 2013;170:215–20.
doi: 10.1016/j.ijcard.2013.10.062
pubmed: 24192334
Xu H, Ruff CT, Giugliano RP, et al. Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF‐TIMI48 trial. J Am Heart Assoc. 2016;5(2):e002587. https://doi.org/10.1161/JAHA.115.002587 .
Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100:1419–26.
doi: 10.1016/j.amjcard.2007.06.034
pubmed: 17950801
Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64:1430–6.
doi: 10.1016/j.jacc.2014.07.957
pubmed: 25277612
Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35:233–41.
doi: 10.1093/eurheartj/eht428
pubmed: 24132190
Fischer Q, Georges JL, Le Feuvre C, et al. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: “OLTAT registry”. Int J Cardiol. 2018;264:64–9.
doi: 10.1016/j.ijcard.2018.03.018
pubmed: 29776575
Verheugt FWA, Ambrosio G, Atar D, et al. Outcomes in newly diagnosed atrial fibrillation and history of acute coronary syndromes: insights from GARFIELD-AF. Am J Med. 2019;132:1431-1440.e7.
doi: 10.1016/j.amjmed.2019.06.008
pubmed: 31306621
Patti G, Pecen L, Lucerna M, et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - a pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol. 2018;270:160–6.
doi: 10.1016/j.ijcard.2018.06.098
pubmed: 30220376
Choi Y, Lee Y, Kim S-H, et al. Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation. Heart . 2022;108(4):285–91. https://doi.org/10.1136/heartjnl-2020-318750 .
Inohara T, Shrader P, Pieper K, et al. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019;213:81–90.
doi: 10.1016/j.ahj.2019.04.007
pubmed: 31129441
Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128:721–8.
doi: 10.1161/CIRCULATIONAHA.113.002927
pubmed: 23861512
pmcid: 3908483
Shah R, Hellkamp A, Lokhnygina Y, et al. Use of concomitant aspirin in patients with atrial fibrillation: findings from the ROCKET AF trial. Am Heart J. 2016;179:77–86.
doi: 10.1016/j.ahj.2016.05.019
pubmed: 27595682
Gawałko M, Lodziński P, Budnik M, et al. Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORP-AF General Long-Term Registry. Int J Clin Pract. 2021;75:e13701.
doi: 10.1111/ijcp.13701
pubmed: 32915461
Lemesle G, Ducrocq G, Elbez Y, et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events. Clin Cardiol. 2017;40:932–9.
doi: 10.1002/clc.22750
pubmed: 28692742
pmcid: 6490437
Shiroto T, Sakata Y, Nochioka K, et al. Clinical benefits and risks of antithrombotic therapy in patients with atrial fibrillation with comorbidities - a report from the CHART-2 Study. Int J Cardiol. 2020;299:160–8.
doi: 10.1016/j.ijcard.2019.09.022
pubmed: 31611087
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. Massachusetts Medical Society. 2011;365:883–91.
doi: 10.1056/NEJMoa1009638
pubmed: 21830957
Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. Elsevier. 2013;170:215–20.
doi: 10.1016/j.ijcard.2013.10.062
pubmed: 24192334
Dabigatran versus warfarin in patients with atrial fibrillation. NEJM. [cited 2022 Mar 21]. Available from: https://doi.org/10.1056/nejmoa0905561 .
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
doi: 10.1056/NEJMoa1107039
pubmed: 21870978
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. Massachusetts Medical Society. 2013;369:2093–104.
doi: 10.1056/NEJMoa1310907
pubmed: 24251359
Kwon O, Park D-W. Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations. JACC: Asia. American College of Cardiology Foundation. 2022;2:1–18.
pubmed: 36340250
pmcid: 9627845
Matteau A, Yeh R, Camenzind E, et al. Balancing long-term risks of ischemic and bleeding complications after percutaneous coronary intervention with drug-eluting stents. Am J Cardiol. 2015;116:686–93.
doi: 10.1016/j.amjcard.2015.05.036
pubmed: 26187674
pmcid: 4670082
Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol. American College of Cardiology Foundation. 2020;75:590–604.
doi: 10.1016/j.jacc.2019.11.058
pubmed: 32057373
Ullah W, Sattar Y, Shaukat M, Fischman DL. Safety and efficacy of anticoagulant monotherapy in atrial fibrillation and stable coronary artery disease: a systematic review and meta-analysis. Eur J Intern Med. 2020;81:54–9.
doi: 10.1016/j.ejim.2020.06.035
pubmed: 32709546
Lee S-R, Rhee T-M, Kang D-Y, Choi E-K, Oh S, Lip GYH. Meta-analysis of oral anticoagulant monotherapy as an antithrombotic strategy in patients with stable coronary artery disease and nonvalvular atrial fibrillation. Am J Cardiol. 2019;124:879–85.
doi: 10.1016/j.amjcard.2019.05.072
pubmed: 31311662
Wernly B, Bhatt DL, Polzin A, Jung C. Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more. J Thromb Thrombolysis. 2020;49:321–4.
doi: 10.1007/s11239-019-02007-4
pubmed: 31797240
Kheiri B, Simpson TF, Stecker EC, et al. Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2020;50:395–8.
doi: 10.1007/s11239-020-02041-7
pubmed: 31981041